It's Goodbye From Me - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

It's Goodbye From Me


Pharmaceutical Technology Europe
Volume 23, Issue 3


Fedra
This issue will mark the last issue for me as Editor of PTE. It's time for me to move on to pastures new and to say my goodbyes. But before I do, I would like to say what a pleasure it has been for me to serve as Editor of Pharmaceutical Technology Europe. I have witnessed some very exciting but also incredibly testing times within the industry during my time as Editor, but I am in great admiration of the work that you do and some of the innovative ways that companies have adapted to withstand the impact of the significant market changes — from economic uncertainties through to patent expirations, the growth of biologics, and strong competition from emerging countries, to name just a few of the challenges. I can, however, guarantee that PTE will continue to keep you updated on all of the latest issues, developments and innovations within your market. We have an incredibly talented team here at Pharmaceutical Technology and I am confident that they will serve you to the best of their ability. I would now like to take this opportunity to thank you so much for your invaluable support of PTE and to introduce you to our very talented new Editor of PTE, Rich Whitworth.

Many thanks and very best wishes,
Fedra Pavlou, Editor-in-Chief


Rich
Let me begin by thanking Fedra for all of her hard work over the past few years, and for handing over a very healthy PTE. I am sure you will all join me in wishing her the very best for the future.

I am excited to be joining the editorial team at PTE so early in the new year and very much looking forward to having real contact with some of you wherever possible. Over the coming months, I plan to continue to nurture our active online community of readers and contributors, which offers such an important extra dimension to PTE and facilitates rapid exchange of new ideas, concerns, and hopes for the future. This online bond between reader, writer—and the editorial team—enables us to guide PTE in directions of your choosing, responding quickly to trends and issues you consider most important in this dynamic industry.

Please join us on LinkedIn ( http://www.pharmtech.com/linkedin), follow us on Twitter ( http://www.pharmtech.com/follow), and get involved!

Many thanks in advance for your continued support,
Rich Whitworth, Editor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here